NPPA slashes cancer drug MRPs by up to 93%; Thiotepa cut by ₹72,921

The drug pricing regulator has slashed retail prices of 543 formulations across 137 non-scheduled cancer medicines, with some cuts exceeding 90% under a trade margin rationalisation framework.